These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24145356)

  • 41. [Clinical study of UFT in renal cell carcinoma].
    Masuda F; Suzuki M; Ohnishi T; Nakada J; Mori Y; Iizuka N; Machida T
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):325-30. PubMed ID: 3918508
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Where does the combination of sorafenib and interferon in renal cell carcinoma stand?
    Flaherty KT
    Cancer; 2010 Jan; 116(1):4-7. PubMed ID: 19890962
    [No Abstract]   [Full Text] [Related]  

  • 43. [Not Available].
    Aktuelle Urol; 2015 Sep; 46(5):356-7. PubMed ID: 26394083
    [No Abstract]   [Full Text] [Related]  

  • 44. The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review.
    Schwartz C; Pfanzelter N; Kuzel TM
    Clin Genitourin Cancer; 2017 Oct; 15(5):e903-e906. PubMed ID: 28624319
    [No Abstract]   [Full Text] [Related]  

  • 45. Pilot phase II trial of amphotericin B and CCNU in renal and colorectal carcinomas.
    Presant CA; Kennedy P; Wiseman C; Gala K; Smith JD; Bouzaglou A; Farbstein M; Multhauf P; Bertrand M; Green L
    Eur J Cancer Clin Oncol; 1986 Mar; 22(3):329-30. PubMed ID: 3709601
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment of established human renal cell carcinoma--experimental treatment with interferon and UFT].
    Onishi T; Iizuka N; Suzuki M; Mori Y; Kondo I; Nakada J; Masuda F; Machida T
    Nihon Gan Chiryo Gakkai Shi; 1988 Jul; 23(7):1498-502. PubMed ID: 3141533
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of recurrent or metastatic renal cell carcinoma.
    Shah RN; Ahmad T; Eisen TG
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1069-80. PubMed ID: 15606334
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Kidney cancer: SWITCHing inconsequential.
    Thoma C
    Nat Rev Urol; 2015 Jun; 12(6):305. PubMed ID: 25986758
    [No Abstract]   [Full Text] [Related]  

  • 49. Maturing of renal cancer therapeutics.
    Stadler WM
    J Clin Oncol; 2014 Mar; 32(8):722-4. PubMed ID: 24516015
    [No Abstract]   [Full Text] [Related]  

  • 50. International perspectives on treating advanced renal cell carcinoma.
    Tanimoto R
    Can J Urol; 2015 Jun; 22(3):7805. PubMed ID: 26068629
    [No Abstract]   [Full Text] [Related]  

  • 51. Metastatic renal cell carcinoma arising in a congenital solitary kidney. Treatment with interferon-containing combinations. A case report and a review of the literature.
    Merimsky O; Laufer R; Chaitchik S
    J Urol (Paris); 1989; 95(4):243-5. PubMed ID: 2529317
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapy and prognostic factors.
    Fumagalli LA; Brivio F
    J Clin Oncol; 2006 Sep; 24(25):4218-9; author reply 4219-20. PubMed ID: 16943541
    [No Abstract]   [Full Text] [Related]  

  • 53. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hutson TE; Ren M; Dutcus C; Larkin J
    Lancet Oncol; 2016 Jan; 17(1):e4-5. PubMed ID: 26758760
    [No Abstract]   [Full Text] [Related]  

  • 54. Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
    Verzoni E; Lanocita R; Procopio G
    Clin Genitourin Cancer; 2012 Jun; 10(2):130-3. PubMed ID: 22226825
    [No Abstract]   [Full Text] [Related]  

  • 55. [Therapy sequence for renal cell carcinoma--new aspects!].
    Miller K
    Aktuelle Urol; 2007 Jan; 38(1):59. PubMed ID: 17290332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Appendix 1: Renal cell carcinoma: MCBS eUpdate published online 10 April 2017(www.esmo.org/Guidelines/Genitourinary-Cancers).
    ESMO Guidelines Committee
    Ann Oncol; 2017 Jul; 28(suppl_4):iv143-iv144. PubMed ID: 28881922
    [No Abstract]   [Full Text] [Related]  

  • 57. Reply from authors re: Camillo Porta, Chiara Paglino. Experience gathered from retrospective series on renal cell carcinoma is useful, but now it is time for a global claim for academically driven prospective studies. Eur Urol 2013;64:71-2: are retrospective data of any value to the specialist treating renal cell carcinoma?
    Weikert S; Grünwald V
    Eur Urol; 2013 Jul; 64(1):72-3. PubMed ID: 23092545
    [No Abstract]   [Full Text] [Related]  

  • 58. [Metastasized renal cell carcinoma - research subjects needed!].
    Aktuelle Urol; 2014 Mar; 45(2):99. PubMed ID: 24700063
    [No Abstract]   [Full Text] [Related]  

  • 59. The National Institute of Health and Clinical Excellence rejects new treatments for renal cell cancer: Cinderella's invitation is cancelled.
    Eisen T
    BJU Int; 2008 Dec; 102(11):1491-2. PubMed ID: 19007367
    [No Abstract]   [Full Text] [Related]  

  • 60. New therapeutic options for renal cell carcinoma.
    Stadler W
    Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.